<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DEXRAZOXANE HYDROCHLORIDE- dexrazoxaneÂ 
			Â </strong><br>Mylan Institutional LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use dexrazoxane for injection safely and effectively.  See full prescribing information for dexrazoxane for injection.<br><br>DEXRAZOXANE for injection, for intravenous use only<br>Initial U.S. Approval: 1995</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m<span class="Sup">2</span> and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use dexrazoxane for injection with doxorubicin initiation. (<a href="#ID_9ba27a2e-3581-4abd-83b8-d6316e620b69">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>Reconstitute vial contents and dilute before use. (<a href="#ID_994b39ab-ce2d-4df6-9e84-dd5a623551e0">2.3</a>)</dd>
<dt>â€¢</dt>
<dd>Administer dexrazoxane for injection by slow I.V. push or rapid drip intravenous infusion from a bag. (<a href="#ID_3ffcaac9-71df-4f32-852d-fd037f63d149">2.1</a>, <a href="#ID_994b39ab-ce2d-4df6-9e84-dd5a623551e0">2.3</a>)</dd>
<dt>â€¢</dt>
<dd>The recommended dosage ratio of dexrazoxane for injection to doxorubicin is 10:1 (e.g., 500 mg/m<span class="Sup">2</span> dexrazoxane for injection to 50 mg/m<span class="Sup">2</span> doxorubicin). Do not administer doxorubicin before dexrazoxane for injection. (<a href="#ID_3ffcaac9-71df-4f32-852d-fd037f63d149">2.1</a>)</dd>
<dt>â€¢</dt>
<dd>Reduce dose by 50% for patients with creatinine clearance &lt; 40 mL/min. (<a href="#ID_87da8652-032c-4335-b280-770316a3e775">2.2</a>, <a href="#ID_b4cbae54-5ce7-41ea-8f7a-05864110cad2">8.7</a>)</dd>
</dl>
<p class="Highlighta">Â  </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">250 mg or 500 mg single dose vials as sterile, pyrogen-free lyophilizates. (<a href="#ID_79cd16d2-0a34-4fde-8812-4f1726742d4f">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Dexrazoxane for injection should not be used with non-anthracycline chemotherapy regimens. (<a href="#ID_65c53345-a5af-426d-970d-8849b8bddaba">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>: Dexrazoxane for injection may increase the myelosuppresive effects of chemotherapeutic agents. Perform hematological monitoring. (<a href="#ID_5c30664a-5b59-4515-a0cd-d18f6669634a">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>Embryo-Fetal Toxicity: Can cause fetal harm. Advise female patients of reproductive potential of the potential hazard to the fetus. (<a href="#ID_459cacf9-952f-4de4-9762-81ab46f91e5b">5.5</a>, <a href="#ID_52e6ec5a-e57b-47be-9f49-6616df21703c">8.1</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">In clinical studies, dexrazoxane for injection was administered to patients also receiving chemotherapeutic agents for cancer. <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> on injection was observed more frequently in patients receiving dexrazoxane for injection versus placebo. (<a href="#ID_8d3253f3-97c5-4076-9f57-fee278bc9ba7">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or </span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Nursing Mothers: Discontinue drug or nursing. (<a href="#ID_56e0d556-f167-41be-84d5-528125faa4fa">8.3</a>)</dd>
</dl></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 5/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1Â Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2Â Dose Modifications</a></h2>
<h2><a href="#section-2.3" class="toc">2.3Â Preparation and Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1Â <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2Â Concomitant Chemotherapy</a></h2>
<h2><a href="#section-5.3" class="toc">5.3Â Cardiac Toxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4Â Secondary Malignancies</a></h2>
<h2><a href="#section-5.5" class="toc">5.5Â Embryo-Fetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1Â Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 	Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6Â Females of Reproductive Potential</a></h2>
<h2><a href="#section-8.6" class="toc">8.7Â <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES </a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1Â <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.2Â Embryo-Fetal Toxicity</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_9ba27a2e-3581-4abd-83b8-d6316e620b69"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Dexrazoxane for injection is indicated for reducing the incidence and severity of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m<span class="Sup">2</span> and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy <span class="Italics">[see <a href="#ID_a17dee35-a338-4779-8c36-2e02f6212a95">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_5f890d94-ea0f-4d6b-adbb-713b419a7f12"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3ffcaac9-71df-4f32-852d-fd037f63d149"></a><a name="section-2.1"></a><p></p>
<h2>2.1Â Recommended Dose</h2>
<p class="First">Administer dexrazoxane for injection by slow I.V. push or rapid drip intravenous infusion from a bag.</p>
<p>The recommended dosage ratio of dexrazoxane for injection to doxorubicin is 10:1 (e.g., 500 mg/m<span class="Sup">2</span> dexrazoxane for injection to 50 mg/m<span class="Sup">2</span> doxorubicin). Do not administer doxorubicin before dexrazoxane for injection. Administer doxorubicin within 30 minutes after the completion of dexrazoxane for injection infusion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_87da8652-032c-4335-b280-770316a3e775"></a><a name="section-2.2"></a><p></p>
<h2>2.2Â Dose Modifications</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3a041f68-931c-4b1f-8ee6-1ba8b465c121"></a><a name="section-2.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Dosing in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></h3>
<p class="First">Reduce dexrazoxane for injection dosage in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance values less than 40 mL/min) by 50% (dexrazoxane for injection to doxorubicin ratio reduced to 5:1; such as 250 mg/m<span class="Sup">2</span> dexrazoxane for injection to 50 mg/m<span class="Sup">2</span> doxorubicin) <span class="Italics">[see <a href="#ID_58f69fd5-1f82-47fd-8b6c-8a80b72c1f9f">Use in Specific Populations (8.6)</a> and <a href="#ID_cddd52ef-0bf3-46fd-8694-0b6fe9cdc7b6">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_628ec118-c6fd-41ab-9008-b593fdd458e6"></a><a name="section-2.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Dosing in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></h3>
<p class="First">Since a doxorubicin dose reduction is recommended in the presence of <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, reduce the dexrazoxane for injection dosage proportionately (maintaining the 10:1 ratio) in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_994b39ab-ce2d-4df6-9e84-dd5a623551e0"></a><a name="section-2.3"></a><p></p>
<h2>2.3Â Preparation and Administration</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6021b586-c563-4742-8bdd-38f98a2d6533"></a><a name="section-2.3.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Preparation and Handling of Infusion Solution</span></span></h3>
<p class="First">Dexrazoxane for injection must be reconstituted with 0.167 Molar (M/6) sodium lactate injection, USP, to give a concentration of 10 mg dexrazoxane for injection for each mL of sodium lactate. The reconstituted solution should be given by slow I.V. push or rapid drip intravenous infusion from a bag. After completing the infusion of dexrazoxane for injection, and prior to a total elapsed time of 30 minutes (from the beginning of the dexrazoxane for injection infusion), the intravenous injection of doxorubicin should be given.</p>
<p>Reconstituted dexrazoxane for injection, when transferred to an empty infusion bag, is stable for 6 hours from the time of reconstitution when stored at controlled room temperature, 20Â° to 25Â°C (68Â° to 77Â°F) or under refrigeration, 2Â° to 8Â°C (36Â° to 46Â°F). DISCARD UNUSED SOLUTIONS.</p>
<p>The reconstituted dexrazoxane for injection solution may be diluted with either 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to a concentration range of 1.3 to 5 mg/mL in intravenous infusion bags. The resultant solutions are stable for 6 hours when stored at controlled room temperature, 20Â° to 25Â°C (68Â° to 77Â°F) or under refrigeration, 2Â° to 8Â°C (36Â° to 46Â°F). DISCARD UNUSED SOLUTIONS.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Solutions containing a precipitate should be discarded.</p>
<p>Use caution when handling and preparing the reconstituted solution. The use of gloves is recommended. If dexrazoxane for injection powder or solutions contact the skin or mucosae, wash exposed area immediately and thoroughly with soap and water. Follow special handling and disposal procedures.<span class="Sup">1</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_592a174f-39e3-43aa-bb81-dc6a34f379f6"></a><a name="section-2.3.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Administration</span></span></h3>
<p class="First">Do not mix dexrazoxane for injection with other drugs.</p>
<p>The reconstituted solution should be given by slow I.V. push or rapid drip intravenous infusion from a bag. After completing the infusion of dexrazoxane for injection, and prior to a total elapsed time of 30 minutes (from the beginning of the dexrazoxane for injection infusion), the intravenous injection of doxorubicin should be given.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_79cd16d2-0a34-4fde-8812-4f1726742d4f"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Dexrazoxane for injection is available in 250 mg or 500 mg single dose vials as sterile, pyrogen-free lyophilizates.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_65c53345-a5af-426d-970d-8849b8bddaba"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Do not use dexrazoxane for injection with non-anthracycline chemotherapy regimens.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_a9dd5b14-47e5-4871-bb24-90daaad1d80c"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5c30664a-5b59-4515-a0cd-d18f6669634a"></a><a name="section-5.1"></a><p></p>
<h2>5.1Â <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Dexrazoxane for injection may add to the <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> caused by chemotherapeutic agents. Obtain a complete blood count prior to and during each course of therapy, and administer dexrazoxane for injection and chemotherapy only when adequate hematologic parameters are met.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a17dee35-a338-4779-8c36-2e02f6212a95"></a><a name="section-5.2"></a><p></p>
<h2>5.2Â Concomitant Chemotherapy</h2>
<p class="First">Only use dexrazoxane for injection in those patients who have received a cumulative doxorubicin dose of 300 mg/m<span class="Sup">2</span> and are continuing with doxorubicin therapy. Do not use with chemotherapy initiation as dexrazoxane for injection may interfere with the antitumor activity of the chemotherapy regimen. In a trial conducted in patients with metastatic breast cancer who were treated with fluorouracil, doxorubicin, and cyclophosphamide (FAC) with or without dexrazoxane for injection starting with their first cycle of FAC therapy, patients who were randomized to receive dexrazoxane for injection had a lower response rate (48% vs. 63%) and shorter time to progression than patients who were randomized to receive placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_be9afdfd-700f-4a0d-8d33-b2f6fade0380"></a><a name="section-5.3"></a><p></p>
<h2>5.3Â Cardiac Toxicity</h2>
<p class="First">Treatment with dexrazoxane for injection does not completely eliminate the risk of anthracycline-induced cardiac toxicity. Monitor cardiac function before and periodically during therapy to assess left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (LVEF). In general, if test results indicate deterioration in cardiac function associated with doxorubicin, the benefit of continued therapy should be carefully evaluated against the risk of producing irreversible cardiac damage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_50f5e717-acdb-4ddb-8e62-4b6ad56415bb"></a><a name="section-5.4"></a><p></p>
<h2>5.4Â Secondary Malignancies</h2>
<p class="First">Secondary malignancies such as <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span> (AML) and <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> (MDS) have been reported in studies of pediatric patients who have received dexrazoxane for injection in combination with chemotherapy. Dexrazoxane for injection is not indicated for use in pediatric patients. Some adult patients who received dexrazoxane for injection in combination with anti-cancer agents known to be carcinogenic have also developed secondary malignancies, including AML and MDS.</p>
<p>Razoxane is the racemic mixture, of which dexrazoxane is the S(+)-enantiomer. Secondary malignancies (primarily <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span>) have been reported in patients treated chronically with oral razoxane. In these patients, the total cumulative dose of razoxane ranged from 26 grams to 480 grams and the duration of treatment was from 42 to 319 weeks. One case of T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, one case of B-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and six to eight cases of cutaneous basal cell or squamous cell carcinoma have also been reported in patients treated with razoxane. Long-term administration of razoxane to rodents was associated with the development of malignancies <span class="Italics">[see <a href="#ID_7e245d75-0835-443b-a6f0-65fa9d8b7feb">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_459cacf9-952f-4de4-9762-81ab46f91e5b"></a><a name="section-5.5"></a><p></p>
<h2>5.5Â Embryo-Fetal Toxicity</h2>
<p class="First">Dexrazoxane for injection can cause fetal harm when administered to pregnant women. Dexrazoxane administration during the period of organogenesis resulted in maternal toxicity, embryotoxicity and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rats and rabbits at doses significantly lower than the clinically recommended dose <span class="Italics">[see <a href="#ID_52e6ec5a-e57b-47be-9f49-6616df21703c">Use in Specific Populations (8.1)</a>]</span>. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.</p>
<p>Advise female patients of reproductive potential to avoid becoming pregnant and to use highly effective contraception during treatment <span class="Italics">[see <a href="#ID_58f69fd5-1f82-47fd-8b6c-8a80b72c1f9f">Use in Specific Populations (8.6)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_a9d90dbc-1962-4ad3-975f-176fb3ec9592"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8d3253f3-97c5-4076-9f57-fee278bc9ba7"></a><a name="section-6.1"></a><p></p>
<h2>6.1Â Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice.</p>
<p>The adverse reaction profile described in this section was identified from randomized, placebo-controlled, double-blind studies in patients with metastatic breast cancer who received the combination of the FAC chemotherapy regimen with or without dexrazoxane for injection. The dose of doxorubicin was 50 mg/m<span class="Sup">2</span> in each of these trials. Treatment was administered every three weeks until disease progression or cardiac toxicity.</p>
<p>Patients in clinical trials who received FAC with dexrazoxane for injection experienced more severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> than patients receiving FAC without dexrazoxane for injection <span class="Italics">[see <a href="#ID_5c30664a-5b59-4515-a0cd-d18f6669634a">Warnings and Precautions (5.1)</a>]</span>.</p>
<p>Table 1 below lists the incidence of adverse reactions for patients receiving FAC with either dexrazoxane for injection or placebo in the breast cancer studies. Adverse experiences occurring during courses 1 through 6 are displayed for patients receiving dexrazoxane for injection or placebo with FAC beginning with their first course of therapy (columns 1 and 3, respectively). Adverse experiences occurring at course 7 and beyond for patients who received placebo with FAC during the first six courses and who then received either dexrazoxane for injection or placebo with FAC are also displayed (columns 2 and 4, respectively).</p>
<p>The adverse reactions listed below in Table 1 demonstrate that the frequency of adverse reaction â€œPain on Injectionâ€? has been greater for dexrazoxane for injection arm, as compared to placebo.</p>
<table width="100%">
<caption><span>Table 1:</span></caption>
<col width="21%">
<col width="21%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="top"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="top"><p class="First"><span class="Bold">Percentage (%) of Breast Cancer Patients with Adverse Reaction</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">FAC + Dexrazoxane</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">FAC + Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Courses 1 to 6</p>
<p>N = 413</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Courses â‰¥ 7</p>
<p>N = 102</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Courses 1 to 6</p>
<p>N = 458</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Courses â‰¥ 7</p>
<p>N = 99</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">94</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">100</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">97</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">98</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">77</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">51</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">84</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">60</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">59</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">42</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">72</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">49</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>/<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">61</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">48</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">58</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">55</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">42</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">27</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">47</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">38</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">34</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">41</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">28</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">34</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">29</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">18</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">21</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> on Injection</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">17</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">17</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Streaking/<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Recall <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reaction</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_40a2474b-eb51-4a07-a230-a103e7edd17d"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No drug interactions have been identified <span class="Italics">[see <a href="#ID_cddd52ef-0bf3-46fd-8694-0b6fe9cdc7b6">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_b632f6e5-f1e8-4626-8b96-271d2dd0876b"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_52e6ec5a-e57b-47be-9f49-6616df21703c"></a><a name="section-8.1"></a><p></p>
<h2>8.1 	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_c8a9ba3f-40bf-4905-a8f7-2b35700e1edc"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Teratogenic Effects. Pregnancy Category D</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_01c63b07-351f-4a8c-b4b5-136646289729"></a><a name="section-8.1.1.1"></a><p></p>
<h4>Risk Summary</h4>
<p class="First">Dexrazoxane for injection can cause fetal harm when administered to pregnant women. Dexrazoxane administration resulted in maternal toxicity, embryotoxicity and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rats and rabbits at doses significantly lower than the clinically recommended dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus <span class="Italics">[see <a href="#ID_459cacf9-952f-4de4-9762-81ab46f91e5b">Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fbbfa5e6-a532-4631-badd-53820f96d806"></a><a name="section-8.1.1.2"></a><p></p>
<h4>Animal Data</h4>
<p class="First">Dexrazoxane resulted in maternal toxicity in rats at doses of â‰¥ 2 mg/kg (1/40 the human dose on a mg/m<span class="Sup">2</span> basis) and embryotoxicity and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at 8 mg/kg (approximately 1/10 the human dose on a mg/m<span class="Sup">2</span> basis) when given daily to pregnant rats during the period of organogenesis. Teratogenic effects in the rat included <span class="product-label-link" type="condition" conceptid="4002465" conceptname="Imperforate anus">imperforate anus</span>, <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>, and <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>. In offspring allowed to develop to maturity, fertility was impaired in the male and female rats treated in utero during organogenesis at 8 mg/kg. In rabbits, doses of â‰¥ 5 mg/kg (approximately 1/10 the human dose on a mg/m<span class="Sup">2</span> basis) daily during the period of organogenesis caused maternal toxicity and doses of 20 mg/kg (1/2 the human dose on a mg/m<span class="Sup">2</span> basis) were embryotoxic and teratogenic. Teratogenic effects in the rabbit included several skeletal malformations such as short tail, rib and thoracic malformations, and soft tissue variations including subcutaneous, eye and cardiac hemorrhagic areas, as well as agenesis of the gallbladder and of the intermediate lobe of the lung.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_56e0d556-f167-41be-84d5-528125faa4fa"></a><a name="section-8.2"></a><p></p>
<h2>8.3 	Nursing Mothers</h2>
<p class="First">It is not known whether dexrazoxane or its metabolites are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from dexrazoxane, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_947b81c0-fbf7-44c9-b935-c45dfe7b9087"></a><a name="section-8.3"></a><p></p>
<h2>8.4 	Pediatric Use</h2>
<p class="First">The safety and effectiveness of dexrazoxane in pediatric patients have not been established <span class="Italics">[see <a href="#ID_50f5e717-acdb-4ddb-8e62-4b6ad56415bb">Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_d2dbf62a-9ff1-41ce-ab95-efbd2c5df39e"></a><a name="section-8.4"></a><p></p>
<h2>8.5 	Geriatric Use</h2>
<p class="First">Clinical studies of dexrazoxane for injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_58f69fd5-1f82-47fd-8b6c-8a80b72c1f9f"></a><a name="section-8.5"></a><p></p>
<h2>8.6Â Females of Reproductive Potential</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ae02306f-c048-409c-83fa-b91e2dc8875c"></a><a name="section-8.5.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Contraception</span></span></h3>
<p class="First">Dexrazoxane for injection can cause fetal harm when administered during pregnancy. Advise female patients of reproductive potential to use highly effective contraception during treatment <span class="Italics">[see <a href="#ID_52e6ec5a-e57b-47be-9f49-6616df21703c">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b4cbae54-5ce7-41ea-8f7a-05864110cad2"></a><a name="section-8.6"></a><p></p>
<h2>8.7Â <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Greater exposure to dexrazoxane may occur in patients with compromised renal function. Reduce the dexrazoxane for injection dose by 50% in patients with creatinine clearance values &lt; 40 mL/min <span class="Italics">[see <a href="#ID_87da8652-032c-4335-b280-770316a3e775">Dosage and Administration (2.2)</a> and <a href="#ID_cddd52ef-0bf3-46fd-8694-0b6fe9cdc7b6">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_b0e14322-d3d7-4b8e-8965-8bb9e198004e"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There are no data on overdosage in the cardioprotective trials; the maximum dose administered during the cardioprotective trials was 1000 mg/m<span class="Sup">2</span> every three weeks.</p>
<p>Disposition studies with dexrazoxane for injection have not been conducted in cancer patients undergoing dialysis, but retention of a significant dose fraction (&gt; 0.4) of the unchanged drug in the plasma pool, minimal tissue partitioning or binding, and availability of greater than 90% of the systemic drug levels in the unbound form suggest that it could be removed using conventional peritoneal or hemodialysis.</p>
<p>There is no known antidote for dexrazoxane. Instances of suspected <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should be managed with good supportive care until resolution of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> and related conditions is complete. Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should include treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, fluid regulation, and maintenance of nutritional requirements.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_7dfcb8cf-213c-411f-9621-dbb4fe719425"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Dexrazoxane for injection, a cardioprotective agent for use in conjunction with doxorubicin, is a sterile, pyrogen-free lyophilizate intended for intravenous administration. </p>
<p>Chemically, dexrazoxane is (S)-4,4'-(1-methyl-1,2-ethanediyl)bis-2,6-piperazinedione. The structural formula is as follows:</p>
<div class="Figure">
<a name="id4956988"></a><img alt="Dexrazoxane Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=77702d60-d1ea-4e4c-a837-aaa813b66064&amp;name=image-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">11</span>H<span class="Sub">16</span>N<span class="Sub">4</span>O<span class="Sub">4</span>Â Â Â Â Â Â M.W. 268.28</p>
</div>
<p>Dexrazoxane, an intracellular chelating agent, is a derivative of EDTA. Dexrazoxane is a white to off-white or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> pink lyophilized powder or cake that melts at 191Â° to 197Â°C. It is sparingly soluble in water and 0.1 N HCl, slightly soluble in ethanol and methanol, and practically insoluble in nonpolar organic solvents. The pK<span class="Sub">a</span> is 2.1. Dexrazoxane has an octanol/water partition coefficient of 0.025 and degrades rapidly above a pH of 7.0.</p>
<p>Each 250 mg vial contains dexrazoxane hydrochloride equivalent to 250 mg dexrazoxane. Hydrochloric Acid, NF is added for pH adjustment. When reconstituted as directed with the 25 mL vial of 0.167 Molar (M/6) Sodium Lactate Injection, USP diluent provided, each mL contains: 10 mg dexrazoxane. The pH of the resultant solution is 3.5 to 5.5.</p>
<p>Each 500 mg vial contains dexrazoxane hydrochloride equivalent to 500 mg dexrazoxane. Hydrochloric Acid, NF is added for pH adjustment. When reconstituted as directed with the 50 mL vial of 0.167 Molar (M/6) Sodium Lactate Injection, USP diluent provided, each mL contains: 10 mg dexrazoxane. The pH of the resultant solution is 3.5 to 5.5.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_b14f3504-8b9d-4150-8d00-52fce93ad85b"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_5e59b066-a628-4288-acde-258de0a85536"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism by which dexrazoxane for injection exerts its cytoprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_cddd52ef-0bf3-46fd-8694-0b6fe9cdc7b6"></a><a name="section-11.2"></a><p></p>
<h2>12.3 	Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of dexrazoxane have been studied in advanced cancer patients with normal renal and hepatic function. The pharmacokinetics of dexrazoxane can be adequately described by a two-compartment open model with first-order elimination. Dexrazoxane has been administered as a 15 minute infusion over a dose range of 60 to 900 mg/m<span class="Sup">2</span> with 60 mg/m<span class="Sup">2</span> of doxorubicin, and at a fixed dose of 500 mg/m<span class="Sup">2</span> with 50 mg/m<span class="Sup">2</span> doxorubicin. The disposition kinetics of dexrazoxane are dose-independent, as shown by linear relationship between the area under plasma concentration-time curves and administered doses ranging from 60 to 900 mg/m<span class="Sup">2</span>. The mean peak plasma concentration of dexrazoxane was 36.5 mcg/mL at 15 minute after intravenous administration of 500 mg/m<span class="Sup">2</span> dose of dexrazoxane for injection over 15 to 30 minutes prior to the 50 mg/m<span class="Sup">2</span> doxorubicin dose.</p>
<p>The important pharmacokinetic parameters of dexrazoxane are summarized in Table 2:</p>
<a name="_RefID0ENDAG"></a><table width="100%">
<caption><span>Table 2: Summary of Mean (% CV<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>) Dexrazoxane Pharmacokinetic Parameters at a Dosage Ratio of 10:1 of Dexrazoxane for Injection:Doxorubicin</span></caption>
<col width="15%">
<col width="16%">
<col width="11%">
<col width="15%">
<col width="13%">
<col width="13%">
<col width="16%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Coefficient of variation</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>Steady-state volume of distribution</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Dose Doxorubicin (mg/m<span class="Sup">2</span>)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Dose</span></p>
<p><span class="Bold">Dexrazoxane</span></p>
<p><span class="Bold">for Injection</span></p>
<p><span class="Bold">(mg/m<span class="Sup">2</span>)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Number of Subjects</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Elimination Half-Life</span></p>
<p><span class="Bold">(h)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Plasma Clearance</span></p>
<p><span class="Bold">(L/h/m<span class="Sup">2</span>)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Renal Clearance</span></p>
<p><span class="Bold">(L/h/m<span class="Sup">2</span>)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a><span class="Bold">Volume of Distribution</span></p>
<p><span class="Bold">(L/m<span class="Sup">2</span>)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">500</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.5 (16)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7.88 (18)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.35 (36)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">22.4 (22)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">60</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">600</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.1 (29)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.25 (31)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">---</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">22.0 (55)</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f3fda32f-b7a9-467c-96d1-05f929ff150e"></a><a name="section-11.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Distribution</span></span></h3>
<p class="First">Following a rapid distributive phase (0.2 to 0.3 hours), dexrazoxane reaches post-distributive equilibrium within 2 to 4 hours. The estimated mean steady-state volume of distribution of dexrazoxane is 22.4 L/m<span class="Sup">2</span> after 500 mg/m<span class="Sup">2</span> of dexrazoxane for injection dose followed by 50 mg/m<span class="Sup">2</span> of doxorubicin, suggesting distribution throughout total body water (25 L/m<span class="Sup">2</span>).</p>
<p><span class="Italics">In vitro</span> studies have shown that dexrazoxane is not bound to plasma proteins.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_070e85b9-2a5a-4836-bdeb-eb184cb6f9e2"></a><a name="section-11.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Metabolism</span></span></h3>
<p class="First">Qualitative metabolism studies with dexrazoxane have confirmed the presence of unchanged drug, a diacid-diamide cleavage product, and two monoacid-monoamide ring products in the urine of animals and man. The metabolite levels were not measured in the pharmacokinetic studies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b5f6b14a-cbe3-42ef-a08f-9cf4aa650e29"></a><a name="section-11.2.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Excretion</span></span></h3>
<p class="First">Urinary excretion plays an important role in the elimination of dexrazoxane. Forty-two percent of a 500 mg/m<span class="Sup">2</span> dose of dexrazoxane for injection was excreted in the urine. Renal clearance averages 3.35 L/h/m<span class="Sup">2</span> after the 500 mg/m<span class="Sup">2</span> dexrazoxane for injection dose followed by 50 mg/m<span class="Sup">2</span> of doxorubicin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2881a220-1da9-47ba-911b-b8751b58b9e4"></a><a name="section-11.2.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Specific Populations</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c223512f-8991-42a3-a11f-a54deb5bab65"></a><a name="section-11.2.4.1"></a><p></p>
<h4>Pediatric</h4>
<p class="First">Pharmacokinetics following dexrazoxane for injection administration have not been evaluated in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5a749368-8430-4769-b213-cf764042959a"></a><a name="section-11.2.4.2"></a><p></p>
<h4>Effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h4>
<p class="First">The pharmacokinetics of dexrazoxane were assessed following a single 15 minute IV infusion of 150 mg/m<span class="Sup">2</span> of dexrazoxane for injection. Dexrazoxane clearance was reduced in subjects with renal dysfunction. Compared with controls, the mean AUC<span class="Sub">0-inf</span> value was 2-fold greater in subjects with moderate (CL<span class="Sub">CR</span> 30 to 50 mL/min) to severe (CL<span class="Sub">CR</span> &lt; 30 mL/min) renal dysfunction. Modeling demonstrated that equivalent exposure (AUC<span class="Sub">-inf</span>) could be achieved if dosing were reduced by 50% in subjects with creatinine clearance values &lt; 40 mL/min compared with control subjects (CL<span class="Sub">CR</span> &gt; 80 mL/min) <span class="Italics">[see <a href="#ID_b4cbae54-5ce7-41ea-8f7a-05864110cad2">Use in Specific Populations (8.7)</a> and <a href="#ID_87da8652-032c-4335-b280-770316a3e775">Dosage and Administration (2.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_05fea6f1-83f0-4c78-8ec6-0e3b40486802"></a><a name="section-11.2.4.3"></a><p></p>
<h4>Effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h4>
<p class="First">Pharmacokinetics following dexrazoxane for injection administration have not been evaluated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The dexrazoxane for injection dose is dependent upon the dose of doxorubicin <span class="Italics">[see <a href="#ID_87da8652-032c-4335-b280-770316a3e775">Dosage and Administration (2.2)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_b51b587e-3f86-45c7-97d0-86f228b4f210"></a><a name="section-11.2.5"></a><p></p>
<h3><span class="Bold"><span class="Italics">Drug Interactions</span></span></h3>
<p class="First">There was no significant change in the pharmacokinetics of doxorubicin (50 mg/m<span class="Sup">2</span>) and its predominant metabolite, doxorubicinol, in the presence of dexrazoxane (500 mg/m<span class="Sup">2</span>) in a crossover study in cancer patients.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_31baa509-f319-41ac-84c1-88f1aae66961"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_7e245d75-0835-443b-a6f0-65fa9d8b7feb"></a><a name="section-12.1"></a><p></p>
<h2>13.1 	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term carcinogenicity studies have been carried out with dexrazoxane in animals. Nevertheless, a study by the National Cancer Institute has reported that long-term dosing with razoxane (the racemic mixture of dexrazoxane, ICRF-187, and its enantiomer ICRF-186) is associated with the development of malignancies in rats and possibly in mice <span class="Italics">[see <a href="#ID_50f5e717-acdb-4ddb-8e62-4b6ad56415bb">Warnings and Precautions (5.4)</a>]</span>.</p>
<p>Dexrazoxane was not mutagenic in the bacterial reverse mutation (Ames) test, but was found to be clastogenic to human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> in vitro and to mouse bone marrow erythrocytes <span class="Italics">in vivo</span> (micronucleus test).</p>
<p>Dexrazoxane for injection has the potential to impair fertility in male patients based on effects in repeat-dose toxicology studies. <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">Testicular atrophy</span> was seen with dexrazoxane administration at doses as low as 30 mg/kg weekly for 6 weeks in rats (1/3 the human dose on a mg/m<span class="Sup">2</span> basis) and as low as 20 mg/kg weekly for 13 weeks in dogs (approximately equal to the human dose on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_a25ee720-87bd-4c97-87e6-eb1311aa4699"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The ability of dexrazoxane for injection to prevent/reduce the incidence and severity of doxorubicin-induced <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> was evaluated in three prospectively randomized placebo-controlled studies. In these studies, patients were treated with a doxorubicin-containing regimen and either dexrazoxane for injection or placebo starting with the first course of chemotherapy. There was no restriction on the cumulative dose of doxorubicin. Cardiac function was assessed by measurement of the LVEF, utilizing resting multigated nuclear medicine (MUGA) scans, and by clinical evaluations. Patients receiving dexrazoxane for injection had significantly smaller mean decreases from baseline in LVEF and lower incidences of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> than the control group; however, in the largest study, patients with advanced breast cancer receiving FAC with dexrazoxane for injection had a lower response rate (48% vs. 63%) and a shorter time to progression than patients who received FAC versus placebo.</p>
<p>In the clinical trials, patients who were initially randomized to receive placebo were allowed to receive dexrazoxane for injection after a cumulative dose of doxorubicin above 300 mg/m<span class="Sup">2</span>. Retrospective historical analyses showed that the risk of experiencing a cardiac event (see Table 3 for definition) at a cumulative dose of doxorubicin above 300 mg/m<span class="Sup">2</span> was greater in the patients who did not receive dexrazoxane for injection beginning with their seventh course of FAC than in the patients who did receive dexrazoxane for injection (HR=13.08; 95% CI: 3.72, 46.03; p &lt; 0.001). Overall, 3% of patients treated with dexrazoxane for injection developed CHF compared with 22% of patients not receiving dexrazoxane for injection.</p>
<p><span class="Bold">Table 3: Definition of Cardiac Events</span></p>
<dl>
<dt>1.</dt>
<dd>Development of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, defined as having two or more of the following:<dl>
<dt>a.</dt>
<dd><span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">Cardiomegaly</span> by X-ray</dd>
<dt>b.</dt>
<dd>Basilar <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span></dd>
<dt>c.</dt>
<dd>S3 Gallop</dd>
<dt>d.</dt>
<dd><span class="product-label-link" type="condition" conceptid="4206307" conceptname="Paroxysmal nocturnal dyspnea">Paroxysmal nocturnal dyspnea</span> and/or <span class="product-label-link" type="condition" conceptid="315361" conceptname="Orthopnea">orthopnea</span> and/or significant <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> on exertion.</dd>
</dl>
</dd>
<dt>2.</dt>
<dd>Decline from baseline in LVEF by â‰¥ 10% and to below the lower limit of normal for the institution.</dd>
<dt>3.</dt>
<dd>Decline in LVEF by â‰¥ 20% from baseline value.</dd>
<dt>4.</dt>
<dd>Decline in LVEF to â‰¥ 5% below lower limit of normal for the institution.</dd>
</dl>
<p>Figure 1 shows the number of patients still on treatment at increasing cumulative doses.</p>
<div class="Figure">
<a name="id-1574503985"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=77702d60-d1ea-4e4c-a837-aaa813b66064&amp;name=image-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_5d829b47-468d-4afb-b564-9c54ec79b3d1"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES </h1>
<p class="First">1. â€œOSHA Hazardous Drugs.â€? OSHA http://www.osha.gov/SLTC/hazardousdrugs/index.html.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_c1c77965-5369-407f-87b9-c6687452ca90"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Dexrazoxane for Injection is available in the following strengths as sterile, pyrogen-free lyophilizates.</p>
<p>NDC 67457-207-25</p>
<p>250 mg single-dose vial with a green flip-top seal, packaged in single vial packs. (This package also contains a 25 mL vial of 0.167 Molar (M/6) Sodium Lactate Injection, USP.)</p>
<p>NDC 67457-208-50</p>
<p>500 mg single-dose vial with a blue flip-top seal, packaged in single vial packs. (This package also contains a 50 mL vial of 0.167 Molar (M/6) Sodium Lactate Injection, USP.)</p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</span> Reconstituted solutions of dexrazoxane for injection are stable for 6 hours at controlled room temperature or under refrigeration, 2Â° to 8Â°C (36Â° to 46Â°F). DISCARD UNUSED SOLUTIONS.</p>
<p>Follow special handling and disposal procedures.<span class="Sup">1</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_1cf9cfa7-2ead-42d0-948c-796e38f96f88"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7cee14c2-5187-4a22-a955-6b98e00f4632"></a><a name="section-16.1"></a><p></p>
<h2>17.1Â <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Treatment with dexrazoxane for injection is associated with <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. Perform hematological monitoring <span class="Italics">[see <a href="#ID_5c30664a-5b59-4515-a0cd-d18f6669634a">Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8718bd51-3c8e-41ca-bb7a-6916632ea485"></a><a name="section-16.2"></a><p></p>
<h2>17.2Â Embryo-Fetal Toxicity</h2>
<p class="First">Counsel patients on pregnancy planning and prevention. Advise female patients of reproductive potential that dexrazoxane for injection can cause fetal harm and to use highly effective contraception during treatment <span class="Italics">[see <a href="#ID_459cacf9-952f-4de4-9762-81ab46f91e5b">Warnings and Precautions (5.5)</a> and <a href="#ID_52e6ec5a-e57b-47be-9f49-6616df21703c">Use in Specific Populations (8.1</a>, <a href="#ID_58f69fd5-1f82-47fd-8b6c-8a80b72c1f9f">8.6)</a>]</span>.</p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Gland Pharma Limited</span><br>D.P. Pally, Dundigal Post<br>Hyderabad-500 043, India</p>
<p>Code No.: AP/DRUGS/103/97</p>
<p>REVISED MAY 2015<br>LEA-019334-03<br>MI:DEXRIJ:R4</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_791bc4fc-43ec-49e8-8c72-d5c631e064ab"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ 250 mgÂ </h1>
<p class="First"><span class="Bold">NDC 67457-207-25</span></p>
<p><span class="Bold">Dexrazoxane for Injection</span><br><span class="Bold">250 mg and</span><br><span class="Bold">0.167M (M/6)</span></p>
<p><span class="Bold">Sodium Lactate Injection, USP</span></p>
<p><span class="Bold">Sterile, pyrogen-free lyophilizate</span></p>
<p><span class="Bold">For Intravenous Use Only</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">1 x 250 mg single-dose vial dexrazoxane</span><br><span class="Bold">1 x 25 mL vial sodium lactate injection, USP as diluent</span></p>
<p><span class="Bold">Each vial contains:</span><br>Dexrazoxane hydrochloride equivalent<br>to 250 mg dexrazoxane.</p>
<p>The pH is adjusted with hydrochloric<br>acid, NF.</p>
<p>This package also contains one 25 mL<br>vial of 0.167M (M/6) sodium lactate<br>injection, USP, as diluent.</p>
<p>Upon reconstitution with 25 mL vial of<br>0.167M (M/6) sodium lactate injection,<br>USP, the pH of the resultant solution is<br>3.5 to 5.5.</p>
<p>Reconstituted solutions are stable for<br>6 hours at controlled room<br>temperature or under refrigeration,<br>2Â° to 8Â°C (36Â° to 46Â°F).</p>
<p>Discard unused solutions.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Made in India</p>
<p>Code No.: AP/DRUGS/103/97</p>
<p>MI:207:2KC:R5</p>
<p>Mylan.com</p>
<div class="Figure">
<a name="id31091174"></a><img alt="Dexrazoxane for Injection 250 and 0.167M (M/6) Sodium Lactate Injection, USP Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=77702d60-d1ea-4e4c-a837-aaa813b66064&amp;name=image-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_51fff34d-7ee7-4762-b33b-bb4b631a9cc6"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ 500 mgÂ </h1>
<p class="First"><span class="Bold">NDC 67457-208-50</span></p>
<p><span class="Bold">Dexrazoxane for Injection</span><br><span class="Bold">500 mg and</span><br><span class="Bold">0.167M (M/6)</span></p>
<p><span class="Bold">Sodium Lactate Injection, USP</span></p>
<p><span class="Bold">Sterile, pyrogen-free lyophilizate</span></p>
<p><span class="Bold">For Intravenous Use Only</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">1 x 500 mg single-dose vial dexrazoxane</span><br><span class="Bold">Rx only 1 x 50 mL vial sodium lactate injection, USP as diluent</span></p>
<p><span class="Bold">Each vial contains:</span><br>Dexrazoxane hydrochloride equivalent to<br>500 mg dexrazoxane.</p>
<p>The pH is adjusted with hydrochloric acid,<br>NF.</p>
<p>This package also contains one 50 mL vial<br>of 0.167M (M/6) sodium lactate injection,<br>USP, as diluent.</p>
<p>Upon reconstitution with 50 mL vial of<br>0.167M (M/6) sodium lactate injection, USP,<br>the pH of the resultant solution is 3.5 to 5.5.</p>
<p>Reconstituted solutions are stable for 6<br>hours at controlled room temperature or<br>under refrigeration, 2Â° to 8Â°C (36Â° to 46Â°F).</p>
<p>Discard unused solutions.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Made in India</p>
<p>Code No.: AP/DRUGS/103/97</p>
<p>MI:208:2KC:R5</p>
<p>Mylan.com</p>
<div class="Figure">
<a name="id31091819"></a><img alt="Dexrazoxane for Injection 500 mg and 0.167M (M/6) Sodium Lactate Injection, USP Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=77702d60-d1ea-4e4c-a837-aaa813b66064&amp;name=image-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEXRAZOXANE HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">dexrazoxane kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-207</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-207-25</td>
<td class="formItem">1  in 1 PACKAGE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">PartÂ #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-DOSE </td>
<td class="formItem">25Â mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">25Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>DEXRAZOXANE HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">dexrazoxane injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-204</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXRAZOXANE HYDROCHLORIDE</strong> (DEXRAZOXANE) </td>
<td class="formItem">DEXRAZOXANE</td>
<td class="formItem">250Â mg Â inÂ 25Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (whitish crystalline powder) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-204-25</td>
<td class="formItem">25 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200752</td>
<td class="formItem">11/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>SODIUM LACTATEÂ 		
					</strong><br><span class="contentTableReg">sodium lactate injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-205</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LACTATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-205-25</td>
<td class="formItem">25 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200752</td>
<td class="formItem">11/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200752</td>
<td class="formItem">11/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEXRAZOXANE HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">dexrazoxane kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-208</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-208-50</td>
<td class="formItem">1  in 1 PACKAGE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">PartÂ #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-DOSE </td>
<td class="formItem">50Â mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">50Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>DEXRAZOXANE HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">dexrazoxane injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-209</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXRAZOXANE HYDROCHLORIDE</strong> (DEXRAZOXANE) </td>
<td class="formItem">DEXRAZOXANE</td>
<td class="formItem">500Â mg Â inÂ 50Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (whitish crystalline powder) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-209-50</td>
<td class="formItem">50 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200752</td>
<td class="formItem">11/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>SODIUM LACTATEÂ 		
					</strong><br><span class="contentTableReg">sodium lactate injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-205</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LACTATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-205-50</td>
<td class="formItem">50 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200752</td>
<td class="formItem">11/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200752</td>
<td class="formItem">11/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Mylan Institutional LLC
							(790384502)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6525cd27-ac93-4f2d-bf6b-fc473cdf1de9</div>
<div>Set id: 77702d60-d1ea-4e4c-a837-aaa813b66064</div>
<div>Version: 5</div>
<div>Effective Time: 20150512</div>
</div>
</div>Â <div class="DistributorName">Mylan Institutional LLC</div></p>
</body></html>
